Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma

Ryan S. Robetorye, Colleen A. Ramsower, Allison C. Rosenthal, Tameson K. Yip, Amy J. Wendel Spiczka, Betty J. Glinsmann-Gibson, Lisa M Rimsza

Research output: Contribution to journalArticle

1 Scopus citations


Diffuse large B cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including germinal center B cell type, activated B cell type, and unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression-profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed prospectively by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified clinical molecular diagnostics laboratory.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalJournal of Hematopathology
Issue number1
StatePublished - Mar 11 2019
Externally publishedYes



  • Cell-of-origin
  • Diffuse large B cell lymphoma
  • Gene expression profiling
  • Lymph2Cx

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Hematology

Cite this